Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.

BACKGROUND

Natalizumab (NTZ) is a monoclonal antibody with an immunosuppressive effect that reduces the inflammation of the central nervous system, and it has been used for the treatment of relapsing-remitting multiple sclerosis (RRMS). In patients with low cellular immune response, systemic mycosis arising from endemic areas may occur.

RESULTS AND

CONCLUSION

In this article, we will describe a case of paracoccidioidomycosis as a complication to treatment with NTZ in an RRMS patient.